Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $36.92 million. The enterprise value is $20.97 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 44.00 million shares outstanding. The number of shares has increased by 11.45% in one year.
| Current Share Class | 44.00M |
| Shares Outstanding | 44.00M |
| Shares Change (YoY) | +11.45% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 13.13% |
| Owned by Institutions (%) | 15.80% |
| Float | 35.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.05, with a Debt / Equity ratio of 0.84.
| Current Ratio | 4.05 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -130.90% and return on invested capital (ROIC) is -38.71%.
| Return on Equity (ROE) | -130.90% |
| Return on Assets (ROA) | -17.80% |
| Return on Invested Capital (ROIC) | -38.71% |
| Return on Capital Employed (ROCE) | -38.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.69M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $103,000 in taxes.
| Income Tax | 103,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.80% in the last 52 weeks. The beta is 0.83, so QNCX's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -7.80% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 25.95 |
| Average Volume (20 Days) | 582,473 |
Short Selling Information
The latest short interest is 1.06 million, so 2.40% of the outstanding shares have been sold short.
| Short Interest | 1.06M |
| Short Previous Month | 1.42M |
| Short % of Shares Out | 2.40% |
| Short % of Float | 3.00% |
| Short Ratio (days to cover) | 7.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.93M |
| Pretax Income | -30.20M |
| Net Income | -60.71M |
| EBITDA | -37.75M |
| EBIT | -37.93M |
| Earnings Per Share (EPS) | -$1.40 |
Full Income StatementBalance Sheet
The company has $31.60 million in cash and $15.65 million in debt, giving a net cash position of $15.95 million or $0.36 per share.
| Cash & Cash Equivalents | 31.60M |
| Total Debt | 15.65M |
| Net Cash | 15.95M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 18.58M |
| Book Value Per Share | 0.42 |
| Working Capital | 25.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.15 million and capital expenditures -$366,000, giving a free cash flow of -$33.52 million.
| Operating Cash Flow | -33.15M |
| Capital Expenditures | -366,000 |
| Free Cash Flow | -33.52M |
| FCF Per Share | -$0.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |